Knee Joint Osteoarthritis. Osteoarthritis of knee
Conditions
Interventions
Intervention 1: Intervention group: Half of the patients enrolled in the study received the drug dapsone at a dose of 50 mg daily for one week and then 100 mg daily until the end of the first month of
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: The patient is 45 years old and older Diagnosis of knee osteoarthritis according to the American College of Rheumatology (ACR) classification Presence of pain as the main complaint of the patient for at least 3 months Severity of involvement grade 2 or higher according to the classification of Kellgren and Lawrence in radiography Ability to follow up for future visits to the hospital
Exclusion criteria
Exclusion criteria: Other inflammatory diseases with joint involvement Patient with previous diagnosis of gout or pseudogout Patient with previous diagnosis of septic arthritis Suffering from anemia DM or uncontrolled HTN Intra-articular injection of corticosteroids in the last 3 months PRP injection in the last three months Injection of intra-articular gels in the last 3 months Any intra-articular injection in the last three months Intramuscular steroid injection in the last month History of arthroscopy or trauma to the affected knee in the last 12 months Surgery history of the involved joint Pregnancy or lactation G6PD deficiency Taking drugs with the risk of hemolysis and hemolytic anemia Drug addiction or history of drug abuse in 12 months History of neoplastic malignancies Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient's pain. Timepoint: At the beginning of the study and 28 days after taking the drug. Method of measurement: Visual analogue scale.;Measure physical function, pain, and stiffness. Timepoint: At the beginning of the study and 28 days after taking the drug. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's quality of life. Timepoint: At the beginning of the study and 28 days after taking the drug. Method of measurement: 36-Item Short Form Survey (SF-36).;Evaluation of the effect of pain on the physical activity of the patient. Timepoint: At the beginning of the study and 28 days after taking the drug. Method of measurement: Nicholas Pain Self-Efficacy Questionnaire.;Assessing the presence of joint fluid effusion. Timepoint: At the beginning of the study and 28 days after taking the drug. Method of measurement: Patient Examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoda Kavosi
Tehran University of Medical Sciences
Outcome results
None listed